The U.S. Food and Drug Administration (FDA) announced Thursday it approved a new drug that “can delay” the onset of stage 3 type 1 diabetes, which is the symptomatic stage of type 1 diabetes.
The drug, teplizumab-mzwv, is to be used to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older, who currently have stage 2 type 1 diabetes, the FDA announced.
